Global Information
회사소개 | 문의 | 비교리스트

황열 : 파이프라인 리뷰

Yellow Fever - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 246029
페이지 정보 영문 57 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


황열 : 파이프라인 리뷰 Yellow Fever - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 57 Pages

황열은 플라비바이러스에 의해 발생하는 급성 전신성 출혈열로, 모기에 의해 전파됩니다. 증상에는 부정맥, 출혈, 구토, 혼수, 섬망, 발열, 두통 및 근육통이 포함됩니다. 황열의 특별한 치료법은 없으나, 증상을 완화하기 위한 치료를 받을 수 있습니다.

황열 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업의 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

황열 개요

치료제 개발

  • 파이프라인 제품의 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

황열 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

황열 치료제 개발에 참여하고 있는 기업

  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • BioCryst Pharmaceuticals Inc
  • Ennaid Therapeutics LLC
  • Fab'entech SA
  • iBio Inc
  • Johnson & Johnson
  • NewLink Genetics Corp
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Valneva SE

약제 개요

황열 : 휴지중인 프로젝트

황열 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Yellow Fever, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Yellow Fever - Pipeline by Bavarian Nordic A/S, H1 2020
  • Yellow Fever - Pipeline by BioCryst Pharmaceuticals Inc, H1 2020
  • Yellow Fever - Pipeline by Emergex Vaccines Ltd, H1 2020
  • Yellow Fever - Pipeline by Ennaid Therapeutics LLC, H1 2020
  • Yellow Fever - Pipeline by Fab'entech SA, H1 2020
  • Yellow Fever - Pipeline by iBio Inc, H1 2020
  • Yellow Fever - Pipeline by Imutex Ltd, H1 2020
  • Yellow Fever - Pipeline by Medigen Inc, H1 2020
  • Yellow Fever - Pipeline by Najit Technologies Inc, H1 2020
  • Yellow Fever - Pipeline by Sanofi Pasteur SA, H1 2020
  • Yellow Fever - Pipeline by Tychan Pte Ltd, H1 2020
  • Yellow Fever - Dormant Projects, H1 2020
  • Yellow Fever - Dormant Projects, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Yellow Fever, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Pipeline Review, H1 2020, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.

Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Yellow Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Yellow Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Yellow Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Yellow Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Yellow Fever (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Yellow Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Yellow Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Yellow Fever - Overview
    • Yellow Fever - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Yellow Fever - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Yellow Fever - Companies Involved in Therapeutics Development
    • Bavarian Nordic A/S
    • BioCryst Pharmaceuticals Inc
    • Emergex Vaccines Ltd
    • Ennaid Therapeutics LLC
    • Fab'entech SA
    • iBio Inc
    • Imutex Ltd
    • Medigen Inc
    • Najit Technologies Inc
    • Sanofi Pasteur SA
    • Tychan Pte Ltd
  • Yellow Fever - Drug Profiles
    • AGS-v PLUS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EMX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galidesivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hydrovax-YFV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Yellow Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TY-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Yellow fever vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Yellow Fever - Dormant Projects
  • Yellow Fever - Product Development Milestones
    • Featured News & Press Releases
      • Nov 18, 2019: WuXi Biologics congratulates Tychan on the world's first yellow fever antibody tested safe and efficacious in human volunteers
      • May 09, 2019: BioCryst completes Phase 1 clinical trial of galidesivir
      • Jan 02, 2019: BioCryst initiates phase 1 clinical trial of Galidesivir
      • Dec 13, 2018: WuXi Biologics congratulates Tychan on first-in-class monoclonal antibody for Yellow fever after record 7 months of development
      • Dec 06, 2018: Tychan Begins Phase I Trials for First Ever Yellow Fever Drug
      • Sep 17, 2018: BioCryst receives additional $3.5 million to fund clinical trials of Galidesivir in Yellow Fever
      • Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
      • Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q